Neurizon granted US patent for lead drug NUZ-001 to treat mTOR pathway-related diseases, ... (ODD) status from the US Food and Drug Administration (FDA) for NUZ-001 in May 2024.

AstraZeneca has launched new lawsuits against four generic drug manufacturers in an ongoing patent battle over its cancer drug Lynparza (olaparib), approved to treat ovarian, pancreatic, prostate ...

The science of drug development will not grind to a halt with sensible pricing reforms — but millions of Americans’ health will suffer if we maintain the status quo.

Similarly, Biological E sought exemption for its Pneumococcal Polysaccharide Conjugate Vaccine (PNEUBEVAX 14), claiming that its novel development and patent status meet the criteria for exemption.

A look at the patents Abbott says Dexcom infringed. The patent that the jury ruled Dexcom did in fact infringe is referred to as the 649 patent. This patent enables an automatic insertion device that ...

The implications of patent eligibility, inventorship, ownership, duty of disclosure, and freedom to operate in AI-augmented drug development present multifaceted inquiries that demand careful ...

An announcement early this month by Mark Cuban’s deep discount drug company that it would sell Coherus Biosciences’ biosimilar version of AbbVie’s Humira has the Illinois drugmaker calling foul.

Of the top 10 selling drugs, 66% of patent applications were filed after the Food and Drug Administration (FDA) approved the drug. Patent thickets mean higher costs for patients. Delays in generic ...

Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition ...